Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1608-1617

  Quintieri, Luigi ^a   Geroni, Cristina ^b   Fantin, Marianna ^a   Battaglia, Rosangela ^b   Rosato, Antonio ^a   Speed, William ^c   Zanovello, Paola ^a   Floreani, Maura ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b NERVIANO MEDICAL SCIENCES   (Italy)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEAMINO 3'',4' ANHYDRO (2'' METHOXY 3'' OXY 4'' MORPHOLINYL)DOXORUBICIN; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DOXORUBICIN; DRUG METABOLITE; KETOCONAZOLE; MONOCLONAL ANTIBODY; NEMORUBICIN; PNU 159682; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG SYNTHESIS; DRUG TRANSFORMATION; ENZYME ACTIVITY; FRAGMENTATION REACTION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MICROSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBON RADIOISOTOPES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HT29 CELLS; HUMANS; JURKAT CELLS; KINETICS; MASS SPECTROMETRY; MICE; MICE, NUDE; MICROSOMES, LIVER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 14644396570     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1845     Document Type: Article

References (47)

1. Ripamonti M, Pezzoni G, Pesenti E, et al. In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells. Br J Cancer 1992;65:703-7.
2. Bakker M, Renes J, Groenhuijzen A, et al. Mechanisms for high methoxymorpholino doxorubicin cytotoxicity in doxorubicin-resistant tumor cell lines. Int J Cancer 1997;73:362-6.
3. Mariani M, Capolongo L, Suarato A, et al. Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR. Invest New Drugs 1994;12:93-7.
4. Danesi R, Agen C, Grandi M, Nardini V, Bevilacqua G, Del Tacca M. 3′-Deamino-3′-(2-methoxy-4-morpholinyl)-doxorubicin (FCE 23762): a new anthracycline derivative with enhanced cytotoxicity and reduced cardiotoxicity. Eur J Cancer 1993;11:1560-5.
5. Sun Y, et al. Efficacy of nemorubicin (MMDX) administered with iodinated oil via hepatic artery (IHA) to patients with unresectable primary hepatocellular carcinoma (HCC): phase II trial. Abstract presented to the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 28 September-1 October 2004; Geneva, Switzerland.
6. Vasey PA, Bissett D, Strolin-Benedetti M, et al. Phase I clinical and pharmacokinetic study of 3′-deamino-3′-(2-methoxy-4-morpholinyl) doxorubicin (FCE 23762). Cancer Res 1995;55:2090-6.
7. Quintieri L, Rosato A, Amboldi N, et al. Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases. Br J Cancer 1999;79:1067-73.
8. Lau DH, Duran GE, Lewis AD, Sikic BI. Metabolic conversion of methoxymorpholinyl doxorubicin: from a DNA strand breaker to a DNA cross-linker. Br J Cancer 1994;70:79-84.
9. Quintieri L, Rosato A, Napoli E, et al. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A. Cancer Res 2000;60:3232-8.
10. Baldwin A, Huang Z, Jounaidi Y, Waxman DJ. Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Arch Biochem Biophys 2003;409:197-206.
11. Breda M, Strolin-Benedetti M, Battaglia R, et al. Species-differences in disposition and reductive metabolism of methoxymorpholinodoxorubicin (PNU 152243), a new potential anticancer agent. Pharmacol Res 2000;41:239-48.
12. Schott B, Robert J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem Pharmacol 1989;38:4069-74.
13. Sessa C, Zucchetti M, Ghielmini M, et al. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243). Cancer Chemother Pharmacol 1999;44:403-10.
14. Suarato A, Caruso M, Geroni C, Capolongo L, Pennella G. From anthracyclines to alkycyclines. In: Book of Abstracts of the 217th American Chemical Society National Meeting, Anaheim, CA, March 21-25 1999. Abstr. CARB-071.
15. Gelboin HV, Krausz KW, Goldfarb I, et al. Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol 1995;50:1841-50.
16. Krausz KW, Yang TJ, Gonzalez FJ, Shou M, Gelboin HV. Inhibitory monoclonal antibodies to human cytochrome P450 2D6. Biochem Pharmacol 1997;54:15-7.
17. Yang TJ, Krausz KW, Shou M, et al. Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol 1998;55:1633-40.
18. Yang TJ, Sai Y, Krausz KW, Gonzalez FJ, Gelboin HV. Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics 1998;8:375-82.
19. Krausz KW, Goldfarb I, Buters JT, Yang TJ, Gonzalez FJ, Gelboin HV. Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. Drug Metab Dispos 2001;29:1410-23.
20. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986;261:5051-60.
21. Jones SB, Terry CM, Lister TE, Johnson DC. Determination of submicromolar concentrations of formaldehyde by liquid chromatography. Anal Chem 1999;71:4030-3.
22. Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995;23:154-8.
23. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996;26:681-93.
24. Hickman D, Wang JP, Wang Y, Unadkat JD. Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 1998;26:207-15.
25. Bourrie M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 1996;277:321-32.
26. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
27. Shou M, Grogan J, Mancewicz JA, et al. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994;33:6450-5.
28. Ueng YF, Kuwabara T, Chun YJ, Guengerich FP. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 1997;36:370-81.
29. Pratesi G, Polizzi D, Perego P, Dal Bo L, Zunino F. Bcl-2 phosphorylation in a human breast carcinoma xenograft: a common event in response to effective DNA-damaging drugs. Biochem Pharmacol 2000;60:77-82.
30. Rodrigues AD. Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem Pharmacol 1994;48:2147-56.
31. Lu AY, Wang RW, Lin JH. Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification. Drug Metab Dispos 2003;31:345-50.
32. Bakker M, Droz JP, Hanauske AR, et al. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients. Br J Cancer 1998;77:139-46.
33. Fokkema E, Verweij J, van Oosterom AT, et al. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study. Br J Cancer 2000;82:767-71.
34. Quintieri L, Lobo Antunes J, Saggioro D, et al. In vitro cytotoxicity, cell cycle effects and DNA-binding properties of PNU-159682. Proc Amer Assoc Cancer Res (2nd ed.) 2003;44:925.
35. Geroni C, Marsiglio A, Amboldi N, Ballinari D, Saggioro D, Quintieri L. Sensitivity of different drug-resistant cell lines to nemorubicin and its metabolites. J Chemother 2004;16(Suppl 1): 169.
36. Guengerich FP. Cytochrome P450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-17.
37. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-23.
38. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997;283:1552-62.
39. Ozdemir V, Kalowa W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000;10:373-88.
40. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90.
41. Patterson LH, Murray GI. Tumour cytochrome P450 and drug activation. Curr Pharm Des 2002;8:1335-47.
42. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002;3:593-603.
43. Martinez C, Garcia-Martin E, Pizarro RM, Garcia-Gamito FJ, Agundez JA. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy. Br J Cancer 2002;87:681-6.
44. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, Gueritte F. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 2002;30:438-45.
45. Yao D, Ding S, Burchell B, Wolf CR, Friedberg T. Detoxication of Vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 2000;294:387-95.
46. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
47. Philip PA, Ali-Sadat S, Doehmer J, et al. Use of V79 cells with stably transfected cytochrome P450 cDNAs in studying the metabolism and effects of cytotoxic drugs. Cancer Chemother Pharmacol 1999;43:59-67.